2026年2月28日是第19个国际罕见病日，今年的主题"不止罕见"。 与此同时，国家卫健委依托国家医学中心和区域医疗中心，加强对罕见病等疑难复杂疾病的诊疗能力建 设，将MDT明确为解决误诊、延迟诊断的重要工具。 据记者不完全梳理，从2025年至今，北京清华长庚医院、北京大学第一医院、北京天坛医院、香港大学 深圳医院、山东大学第二人民医院等超过40家医疗机构建立了罕见病相关诊疗中心，普遍提供罕见病 MDT服务。 据北京病痛挑战公益基金会联合弗若斯特沙利文联合发布的《2026罕见病行业趋势观察报告》（下 称"报告"），中国人群中已知的罕见病逾4000种，罕见病患者规模约2000万，涉及大量家庭和长期医疗 需求。这也意味着，从疾病谱特征和患者规模来看，罕见病在中国同样并非边缘性医疗问题，并在多部 门协同推进下，已从单一医疗问题拓展为涵盖科研、产业、监管与支付的综合性公共议题。 2025年，中国全年共批准罕见病用药约48款，超过17款来自中国企业。在这些科研成果加速转化为临床 可及治疗选择的同时，罕见病确诊难的问题也正加速破局。 患者平均诊断时间从四年缩短至四周 身体不可控制地发胖，血压出现了问题，走路时会在没有外力 ...

2025年共批准罕见病用药约48款。 2026年2月28日是第19个国际罕见病日，今年的主题"不止罕见"。 据北京病痛挑战公益基金会联合弗若斯特沙利文联合发布的《2026罕见病行业趋势观察报告》（下 称"报告"），中国人群中已知的罕见病逾4000种，罕见病患者规模约2000万，涉及大量家庭和长期医疗 需求。这也意味着，从疾病谱特征和患者规模来看，罕见病在中国同样并非边缘性医疗问题，并在多部 门协同推进下，已从单一医疗问题拓展为涵盖科研、产业、监管与支付的综合性公共议题。 2025年，中国全年共批准罕见病用药约48款，超过17款来自中国企业。在这些科研成果加速转化为临床 可及治疗选择的同时，罕见病确诊难的问题也正加速破局。 患者平均诊断时间从四年缩短至四周 由于早期临床表型多且不典型，小陈在病友群中发现，像她一样忽视疾病、走错科室或被医生误诊的情 况，并不少见。罕见病患者的诊疗路径，往往始于反复、非特异性的症状出现，却止于漫长的误诊与延 迟确诊。 近年来，医疗机构对于罕见病诊疗的规范化培训、多项指南发布以及基因检测技术、多学科诊疗 （MDT）模式的普及，显著缩短了罕见病患者确诊时间。 2025年《国家医疗质量安 ...

（来源：上观新闻） 从4年到4周，未来诊断会更快更准 今天（2月28日）是第19个国际罕见病日，就在刚过去的中国春节假期里，两条和罕见病有关的话题引 爆全网。 一条是登上国际顶刊《自然》的上海医学成果：上海交通大学医学院附属新华医院携手上海交通大学人 工智能学院发布全球首个可溯源罕见病AI诊断系统——DeepRare。该应用已服务全球600多家顶尖医疗 科研机构，诊断精度刷新世界纪录。 另一条是美剧《实习医生格蕾》男演员埃里克·迪恩因渐冻症离世，年仅53岁，去年4月他透露了自己罹 患这一罕见病，不到一年，噩耗就传来。同为渐冻症患者的京东前副总裁蔡磊发声："遗憾未能联系上 他，本可以分享经验教训以及最新的药物研发希望。" 如果说罕见病如同医学的"死角"，那么眼下，这一则好消息、一则坏消息，均指向着全球罕见病领域的 点点"新光"：对全球超过3亿罕见病患者而言，原本的就医常态——"诊断难、用药难"的艰难旅程，正 因人工智能（AI）的深度介入迎来拐点。有业内人士甚至预言，2026年或是罕见病新药爆发元年。 根据《中国罕见病定义研究报告》，在我国，新生儿发病率小于万分之一，或患病率小于万分之一，或 患病人数小于14万的 ...

Core Insights - The medical AI industry is experiencing high growth despite not yet achieving scalable profitability, with the Chinese solutions market projected to grow from 16.4 billion yuan in 2024 to 35.3 billion yuan by 2030, reflecting a CAGR of 13.63% [1] - Significant changes in medical AI by 2025 include breakthroughs in large models and increased participation from medical institutions [1] - The deployment of large models in hospitals is accelerating, with all top 100 hospitals in China having completed large model deployments by May 2025, and 38 hospitals developing 55 vertical medical models tailored to their needs [1] Market Growth - The medical AI market in China is expected to expand significantly, with a projected market size of 35.3 billion yuan by 2030 [1] - The integration of various disciplines such as computer science, industrial engineering, and medicine is driving the growth of medical AI [1] Technological Advancements - The introduction of DeepSeek-R1 has lowered the entry barriers for large models, prompting hospital administrators to actively deploy necessary infrastructure [1] - Innovations such as parameter-efficient fine-tuning (PEFT) and mixture of experts (MoE) are enhancing the capabilities of large models [1] Doctor Engagement - Doctors are showing greater enthusiasm for practical applications of large models compared to traditional AI, with some circumventing procurement restrictions to continue research [2] - Over 90% of doctors who have used related AI tools report positive feedback, indicating that AI can enhance surgical precision and reduce complication rates [4] Policy Support - Recent policies are increasingly supportive of AI in healthcare, aiming to establish high-quality data sets and trusted data spaces by 2027 [6] - The implementation of guidelines for AI and medical applications is expected to create a conducive environment for the development of large models [6] Challenges in Commercialization - The value generated by AI in different deployment environments is inconsistent, making it difficult for hospitals to accurately assess benefits and hindering commercialization [7] - Short-term interests of hospitals and doctors often conflict, with AI deployment benefiting doctors but not necessarily translating to immediate hospital gains [8] Long-term Perspectives - In the long term, improved surgical quality through AI could enhance hospital reputation and attract more patients, benefiting both departments and doctors [10] - AI's ability to save time for doctors may lead to increased research opportunities, enhancing both individual and institutional capabilities [11] Specialty Focus: Thoracic Surgery - Thoracic surgery has a high demand for AI to improve operational efficiency and reduce redundant diagnostics [16] - AI applications in thoracic surgery have shown significant efficiency improvements, with diagnostic times reduced by up to 84% in some cases [18] - The introduction of AI in complex surgical planning has been shown to optimize procedures and reduce risks associated with needle placement [19] Data Governance and Assetization - The establishment of data as a production factor is accelerating the exploration of data assetization in healthcare, with a focus on efficient data governance and reuse [27] - The development of trusted data spaces is crucial for facilitating secure data sharing among healthcare stakeholders, promoting deeper integration and utilization of medical data [30]

Group 1 - The global rare disease patient population exceeds 300 million, with over 6,000 rare diseases identified, yet less than 5% have effective treatments available [1] - Advances in genomics and artificial intelligence are providing new hope for precise diagnosis and treatment of rare diseases [1][2] - The Hong Kong Genome Center has recruited over 53,000 participants since its full operation in 2021, aiming to establish a genomic database primarily for the South China population [1] Group 2 - The Greater Bay Area and Yangtze River Delta regions are witnessing the emergence of local leading companies in cell and gene therapy, such as BGI Genomics and Fosun Kite [2] - A three-year action plan was launched in May to develop common technology platforms in gene editing and organoids, with a special fund of 1 billion yuan to support cross-regional projects [2] - The importance of integrating multi-omics technologies into diagnostic laboratories is emphasized, alongside the need for data sharing and AI technologies [2] Group 3 - Beijing Union Medical College Hospital is enhancing rare disease diagnosis through data sharing and large model technology, significantly improving diagnostic efficiency [3] - The establishment of a national rare disease diagnosis collaboration network and the development of AI-assisted diagnostic tools have been key innovations in improving treatment efficiency [3] - The International Rare Disease Association and the Hong Kong Genome Center co-hosted a conference that attracted nearly 300 medical professionals and researchers from over 20 countries, focusing on clinical genetics, genomics, and data sharing [3]

Core Viewpoint - The rapid adoption of artificial intelligence (AI) in China's healthcare sector is transforming hospitals, enhancing efficiency, and creating new opportunities for patient care and management [2][3][5]. Group 1: AI Adoption in Hospitals - Major hospitals in China, including Peking Union Medical College Hospital, have launched multiple AI products aimed at improving clinical and management processes, such as the "Xiehe·Taichu" rare disease model and various intelligent decision-making systems [3][4]. - By 2024, the top 100 hospitals in China have released at least 60 vertical models in various medical fields, indicating a significant shift towards AI integration in healthcare [4][5]. Group 2: Competitive Landscape - The competition among top-tier hospitals to adopt AI technologies is intensifying, with many hospitals forming partnerships to enhance their capabilities and attract specific patient demographics [6][8]. - The trend of "cyber territory" expansion is evident, as hospitals seek to leverage AI to improve patient retention and operational efficiency [6][9]. Group 3: Challenges for Regional Hospitals - Regional hospitals are facing increasing pressure due to the dual competition from both grassroots medical institutions and top-tier hospitals, leading to a wave of mergers among regional hospitals [12][14]. - The rise of AI and advanced medical technologies is contributing to a "third medical revolution," which is raising standards and altering the operational models of healthcare institutions [13][14]. Group 4: Future of Healthcare - The future of healthcare may evolve into a "distributed examination, centralized diagnosis" model, where hospitals must adapt to new roles or risk becoming obsolete [14][15]. - The integration of AI and other technologies is not merely about investment; it requires a comprehensive approach to effectively implement these innovations in healthcare settings [15].

Core Viewpoint - The rapid adoption of artificial intelligence (AI) in China's top hospitals reflects a broader trend in the healthcare industry, driven by the need to enhance efficiency and maintain competitiveness in the face of technological advancements [2][3][4]. Group 1: AI Adoption in Hospitals - Beijing Union Medical College Hospital has launched multiple AI products, including the first rare disease model "Xiehe·Taichu" and various decision support systems for surgeries and critical care [2][3]. - Since the beginning of 2024, at least 60 vertical large models have been released by the top 100 hospitals in China, covering various medical fields and achieving several "national firsts" [3]. - Shanghai Ruijin Hospital has developed over 30 AI applications, completing 1.33 million AI-assisted diagnoses in the past year [3]. Group 2: Competitive Landscape - The competition among major hospitals is intensifying, particularly in specialized fields, as they seek to leverage AI for better patient outcomes and operational efficiency [4][5]. - Hospitals are increasingly forming collaborations with grassroots medical institutions to enhance early screening for diseases like Alzheimer's, indicating a shift towards integrated healthcare models [6][8]. Group 3: Challenges for Regional Hospitals - The rise of AI and advanced technologies is creating pressure on regional hospitals, which are facing consolidation and competition from both grassroots facilities and top-tier hospitals [10][13]. - There have been multiple mergers among regional hospitals in 2023, highlighting the ongoing challenges and the need for these institutions to adapt to the changing healthcare landscape [10]. - The increasing number of tertiary hospitals in China, which has grown by nearly 1.8 times since 2011, is contributing to the survival crisis for many regional hospitals [13][14]. Group 4: Future of Healthcare - The integration of IoT, sensing technologies, and AI is being referred to as the "third medical revolution," which is expected to redefine healthcare delivery and operational standards [11]. - A potential future model of healthcare may involve "distributed examination and centralized diagnosis," which could further impact the roles of various hospitals [13][14].

Group 1 - The core viewpoint of the article highlights the rapid integration of large language models into the healthcare system, with 98 out of the top 100 hospitals in China claiming to have completed model deployment by April 30, 2025 [1] - Among these hospitals, 38 have developed 55 vertical medical models tailored to their specific needs based on general models [1][4] - The shift from "buyers" to "developers" indicates that doctors are becoming crucial contributors to AI development in healthcare [2][12] Group 2 - The emergence of specialized models marks a new era in healthcare AI, with hospitals increasingly focusing on vertical models that address specific diseases and clinical needs [4][6] - The DeepSeek model has significantly lowered the barriers for hospitals to deploy large models, allowing even those with no prior experience to customize and implement them [4][11] - As of April 30, 2025, there are 22 specialized vertical models in development, covering various medical fields such as cardiology, nephrology, and oncology [7][9] Group 3 - The collaboration between hospitals and enterprises remains the dominant model for developing vertical medical models, although independent hospital development is on the rise [13][15] - Major companies like Huawei, China Telecom, and iFlytek are actively involved in the development of these vertical models, indicating a trend towards increased collaboration between hospitals and tech firms [16][19] - The regulatory landscape for large models is evolving, with potential classification as medical devices requiring rigorous approval processes [19][20]

Group 1: AI in Healthcare Overview - The "AI + Healthcare" trend is gaining momentum, with significant interest from various stakeholders including pharmaceutical giants and diagnostic companies, as well as hospitals and internet healthcare platforms [1] - The "AI + Healthcare" sector is expected to be a major investment opportunity throughout 2025, with related stocks experiencing substantial price increases [1] Group 2: Drug Development Innovations - AI is anticipated to break through bottlenecks in drug development, which has traditionally been a lengthy and costly process with low success rates [4] - Compared to traditional drug development, AI can reduce the time for drug discovery and preclinical research by nearly 40%, and increase the success rate of clinical new drug development from 12% to approximately 14% [5] - AI applications in drug development include drug target discovery, molecular design, compound screening, and clinical trials, significantly enhancing efficiency and reducing costs [5][6] Group 3: AI in Diagnostics - AI platforms like DeepSeek are enhancing diagnostic accuracy and efficiency, providing personalized medication suggestions based on patient data [8] - Over 100 hospitals in China have implemented DeepSeek for various applications, including clinical diagnosis and management [8] - AI technologies are also being utilized in medical imaging for assisting diagnoses, optimizing clinical trial designs, and improving patient management [9] Group 4: Market Performance and Investment - The AI pharmaceutical sector has seen a significant rise, with the sector's cumulative increase reaching 30.96% from February 5 to March 24 [11] - Individual stocks such as Anbiping have experienced remarkable growth, with a cumulative increase of 98.87% during the same period, driven by their involvement in AI [11] - Institutions are optimistic about the growth potential of the "AI + Healthcare" sector, predicting a global market size increase from $13.7 billion in 2022 to $155.3 billion by 2030, with a CAGR of 35.5% [12]